Glp2-Trz is an advanced synthetic research peptide designed for in vitro and preclinical exploration of enterotropic signaling, mucosal barrier repair, and multi-receptor metabolic cross-talk. Synthesized under strict quality standards, this compound serves as a vital tool for biomedical laboratories investigating intestinal epithelium homeostasis and incretin-pathway kinetics.
Glp2-Trz is an advanced synthetic research peptide designed for in vitro and preclinical exploration of enterotropic signaling, mucosal barrier repair, and multi-receptor metabolic cross-talk. Synthesized under strict quality standards, this compound serves as a vital tool for biomedical laboratories investigating intestinal epithelium homeostasis and incretin-pathway kinetics.
Glp2-Trz is a specialized synthetic research compound engineered for in vitro and preclinical investigation into gut-barrier function, mucosal integrity, and multi-receptor signaling dynamics. Combining functional motifs from glucagon-like peptide-2 (GLP-2) and multi-incretin scaffolds, Glp2-Trz enables researchers to evaluate enterotropic mucosal repair and metabolic cross-talk in controlled laboratory environments.
Supplied exclusively as a lyophilized powder for scientific investigation, Glp2-Trz allows laboratory investigators to study the structural and functional adaptations of the gastrointestinal lining. By integrating domain structures that target enterotropic pathways alongside metabolic incretin nodes, the compound provides a unique model for analyzing cell survival, crypt cell proliferation, and tight-junction protein expression in cellular and tissue assays.
The molecular design of Glp2-Trz incorporates specific amino acid substitutions intended to enhance resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), while retaining high binding affinity for the GLP-2 receptor (GLP-2R). In native physiological systems, endogenous GLP-2 exhibits a rapid plasma half-life due to cleavage at the Alanine-2 position. Glp2-Trz addresses this metabolic instability by utilizing modified N-terminal residues and side-chain linkers that stabilize the alpha-helical conformation required for optimal receptor engagement.
In vitro competitive binding studies demonstrate that Glp2-Trz selectively activates GLP-2R expressed on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells. Furthermore, preliminary structural modeling suggests that its hybrid backbone maintains secondary target interaction, permitting researchers to explore potential co-stimulation across adjacent G-protein coupled receptors (GPCRs). Investigators utilizing Glp2-Trz research compounds can examine how receptor dimerization and biased agonism alter intracellular signaling cascades compared to monomeric native peptides.
Preclinical studies evaluating GLP-2 analogs and related chimeric compounds demonstrate significant activity in driving intestinal adaptation and epithelial repair. In animal models of intestinal mucositis and inflammatory bowel conditions, administration of GLP-2R agonists is associated with marked increases in villus height, crypt depth, and total mucosal mass. These changes are primarily mediated through the local release of insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF) downstream of subepithelial myofibroblast activation.
In vitro assays utilizing intestinal organoids and Caco-2 cell monolayers show that exposure to Glp2-Trz upregulates key tight-junction proteins, including Claudin-1, Occludin, and ZO-1. This enhancement of cellular junctions correlates with reduced paracellular permeability in trans-epithelial electrical resistance (TEER) measurements. Researchers exploring intestinal permeability models frequently reference data from our research library hub to contextualize how novel enterotropic agonists protect against cytotoxic challenge and bacterial translocation.
To properly position Glp2-Trz within current scientific literature, it is essential to compare its binding profile and physiological targets with established enterotropic agents and multi-incretin agonists. While traditional compounds target single pathways, chimeric and co-agonist structures offer broader scope for analyzing complex systemic responses.
Unlike dedicated mono-agonists such as native GLP-2 or single-target analogs, Glp2-Trz bridges mucosal trophic support with metabolic receptor activation. For instance, while classical single-target compounds evaluate isolated villus expansion, multi-target frameworks like Tirzepatide mechanisms focus heavily on GIP and GLP-1 co-stimulation for glycemic and lipolytic pathways. Similarly, triple-agonist models such as Retatrutide research models engage GCGR, GIPR, and GLP-1R simultaneously. Glp2-Trz provides a distinct paradigm by prioritizing intestinal mucosal architecture while preserving ink-line cross-talk with broader incretin pathways. Researchers seeking a comprehensive inventory of comparative compounds can review our full spectrum of research peptides to design multi-arm comparative studies.
Upon binding to GLP-2R, Glp2-Trz stimulates adenylate cyclase via Gαs protein coupling, triggering a robust rise in intracellular cyclic adenosine monophosphate (cAMP). This intracellular cAMP accumulation activates protein kinase A (PKA) and the exchange protein directly activated by cAMP (EPAC2), initiating downstream transcription factors such as CREB. In vitro studies confirm that this pathway drives cellular survival programs, suppressing apoptosis induced by pro-inflammatory cytokines such as TNF-α and IFN-γ.
Additionally, signal transduction through Glp2-Trz involves the secondary activation of the PI3K/Akt and MAPK/ERK1/2 cascades. These pathways foster translation of mucosal repair proteins and accelerate epithelial cell migration across damaged basolateral membranes. Laboratory assays confirm that the synthetic modifications in Glp2-Trz protect the peptide sequence from immediate proteolytic cleavage by neutral endopeptidases (NEP) and DPP-4, extending incubation windows in cell culture media without rapid activity loss.
Glp2-Trz is supplied as a sterile, lyophilized cake intended strictly for laboratory research use. To preserve structural integrity and prevent aggregation, researchers must adhere to precise reconstitution protocols using aseptic technique within a certified laminar flow hood.
Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the downstream assay. Solvent should be introduced slowly down the inner glass wall of the vial, followed by gentle swirl motion. Never vortex high-purity peptides, as mechanical shear stress can disrupt secondary peptide folding. For long-term stability, reconstituted stock solutions should be aliquoted into polypropylene microcentrifuge tubes to prevent freeze-thaw cycles and stored at -80°C. Unreconstituted lyophilized vials must be kept at -20°C in a desiccated environment away from light.
At PX1 Research, we adhere to stringent analytical protocols to ensure that every lot of Glp2-Trz meets the uncompromising demands of modern scientific research. Chemical fidelity and structural authenticity are confirmed through dual-stage analytical testing performed by independent ISO 17025 accredited testing facilities.
Purity is quantitatively determined using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity of ≥99.0%. Molecular mass identity is verified via Electrospray Ionization Mass Spectrometry (ESI-MS), matching the calculated theoretical molecular weight down to the exact dalton. Furthermore, every batch undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to verify that bacterial endotoxin levels remain below 0.01 EU/mg, preventing confounding inflammatory responses in cell cultures and animal models.
Securing reliable, high-purity research materials is fundamental to reproducible experimental outcomes. PX1 Research provides fully transparent lot traceability, supplying a comprehensive Certificate of Analysis (COA) containing raw HPLC chromatograms and mass spectra with every shipped order.
All PX1 Research compounds are manufactured in domestic, GMP-compliant facilities located in the United States. To support institutional timelines, orders ship directly from our state-of-the-art dispatch hubs in California and Arizona with same-day fulfillment for orders placed Monday through Friday before cut-off times. Academic laboratories, biotechnology firms, and contract research organizations seeking high-volume orders or custom synthesis services can establish institutional accounts through our wholesale program.
What is the primary research application of Glp2-Trz?
Glp2-Trz is utilized in laboratory research to study intestinal epithelial cell proliferation, mucosal barrier repair, tight-junction expression, and receptor cross-talk between GLP-2 signaling pathways and broader incretin networks.
How is the purity of Glp2-Trz verified at PX1 Research?
Every lot of Glp2-Trz undergoes rigorous testing at an independent ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (≥99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for mass verification.
What are the endotoxin limits for PX1 Research compounds?
PX1 Research enforces strict endotoxin controls, verifying that Glp2-Trz batches contain less than 0.01 EU/mg via chromogenic LAL assays to prevent interference in delicate cell culture and preclinical assays.
What diluent should be used to reconstitute Glp2-Trz for laboratory assays?
Reconstitution is typically carried out using sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4). The choice of solvent depends on the specific requirements of the planned in vitro or ex vivo protocol.
How should reconstituted Glp2-Trz be stored to maintain stability?
Reconstituted solutions should be divided into single-use aliquots in polypropylene tubes and stored at -80°C to avoid degradation from repeated freeze-thaw cycles. Lyophilized vials should be stored at -20°C.
Where are PX1 Research products manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona, featuring same-day shipping for qualifying orders placed Monday through Friday.
Is Glp2-Trz approved for human consumption or clinical administration?
No. Glp2-Trz is strictly a research compound supplied for in vitro, ex vivo, and preclinical animal laboratory experimentation. It is not for human or veterinary use, therapy, or clinical application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.